{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:15:05Z","timestamp":1791400505996,"version":"4.3.3"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.coph.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T16:55:41Z","timestamp":1550595341000},"page":"62-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics"],"prefix":"10.1016","volume":"44","author":[{"given":"Kevin","family":"Mullane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1191","authenticated-orcid":false,"given":"Michael","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.01.004_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","article-title":"2018 Alzheimer\u2019s disease facts and figures","volume":"14","author":"Alzheimer\u2019s Association","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_sbref0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2307\/3350070","article-title":"From senility to Alzheimer\u2019s disease: the rise of the Alzheimer\u2019s disease movement","volume":"67","author":"Fox","year":"1989","journal-title":"Milbank Q"},{"key":"10.1016\/j.coph.2019.01.004_sbref0015","series-title":"The Myth of Alzheimer\u2019s Disease","author":"Whitehouse","year":"2008"},{"key":"10.1016\/j.coph.2019.01.004_bib0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/journalofethics.2017.19.7.msoc1-1707","article-title":"Transcending the tragedy discourse of dementia: an ethical imperative for promoting selfhood, meaningful relationships, and well-being","volume":"19","author":"Reed","year":"2017","journal-title":"AMA J Ethics"},{"key":"10.1016\/j.coph.2019.01.004_bib0025","series-title":"Kulturen Der Sorge","first-page":"163","article-title":"The Alzheimerization of growing old","author":"Beard","year":"2018"},{"key":"10.1016\/j.coph.2019.01.004_sbref0030","series-title":"40 Years of Alzheimer\u2019s Research Failure: Now What?","author":"Khachaturian","year":"2018"},{"key":"10.1016\/j.coph.2019.01.004_sbref0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bcp.2018.09.026","article-title":"Alzheimer\u2019s Disease (AD) therapeutics \u2013 1: repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality","volume":"158","author":"Mullane","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2019.01.004_sbref0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bcp.2018.09.027","article-title":"Alzheimer\u2019s Disease (AD) therapeutics \u2013 2: beyond amyloid \u2013 re-defining AD and its causality to discover effective therapeutics","volume":"158","author":"Mullane","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2019.01.004_sbref0045","series-title":"Colloquium Series on Neurobiology of Alzheimer\u2019s Disease #1","first-page":"1","article-title":"Molecular pathology of Alzheimer\u2019s disease","author":"Castellani","year":"2014"},{"key":"10.1016\/j.coph.2019.01.004_bib0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jhmas\/42.3.327","article-title":"The history of Alzheimer\u2019s disease: three debates","volume":"42","author":"Beach","year":"1987","journal-title":"J History Med Allied Sci"},{"key":"10.1016\/j.coph.2019.01.004_bib0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4321\/S0213-61632015000100004","article-title":"Dementia DSM-IV\/ICD-10 or neurocognitive disorder DSM-5?","volume":"29","author":"Domenech","year":"2015","journal-title":"Eur J Psychiatry"},{"key":"10.1016\/j.coph.2019.01.004_sbref0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bcp.2013.11.017","article-title":"The end of Alzheimer\u2019s disease\u2014from biochemical pharmacology to ecopsychosociology: a personal perspective","volume":"88","author":"Whitehouse","year":"2014","journal-title":"Biochem Phamacol"},{"key":"10.1016\/j.coph.2019.01.004_sbref0065","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","article-title":"Questions concerning the role of amyloid-\u03b2 in the definition, aetiology and diagnosis of Alzheimer\u2019s disease","volume":"136","author":"Morris","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2019.01.004_bib0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.coph.2019.01.004_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/NEN.0b013e3181919a48","article-title":"Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship","volume":"68","author":"Nelson","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0080","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d","volume":"8","author":"Stelzmann","year":"1995","journal-title":"Clin Anat"},{"key":"10.1016\/j.coph.2019.01.004_sbref0085","series-title":"Alzheimer: 100 Years and Beyond. Research and Perspectives in Alzheimer\u2019s Disease","first-page":"13","article-title":"The history of Alois Alzheimer\u2019s first case Auguste D. How did the eponym \u201cAlzheimer\u2019s Disease\u201d came into being?","author":"Maurer","year":"2006"},{"key":"10.1016\/j.coph.2019.01.004_bib0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/gps.930050603","article-title":"Alzheimer\u2019s disease: a conceptual history","volume":"5","author":"Berrios","year":"1990","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.coph.2019.01.004_bib0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jamda.2016.06.017","article-title":"Alzheimer mythology: a time to think out of the box","volume":"17","author":"Morley","year":"2016","journal-title":"J Am Med Direct Assoc"},{"key":"10.1016\/j.coph.2019.01.004_bib0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s004060050027","article-title":"The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections","volume":"248","author":"M\u00f6ller","year":"1998","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_sbref0105","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/awn256","article-title":"Oskar Fischer and the study of dementia","volume":"132","author":"Godert","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.coph.2019.01.004_sbref0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1076\/jhin.9.3.250.1792","article-title":"Simon Carter Fuller M.D. (1872\u20131953): American pioneer in Alzheimer\u2019s Disease research","volume":"8","author":"Kaplan","year":"2000","journal-title":"J History Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","article-title":"The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects","volume":"114","author":"Blessed","year":"1968","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.coph.2019.01.004_bib0120","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaneurol.2015.1721","article-title":"Characterizing apolipoprotein E \u03b54 carriers and noncarriers with the clinical diagnosis of mild to moderate alzheimer dementia and minimal \u03b2-amyloid peptide plaques","volume":"72","author":"Monsell","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3233\/JAD-2011-111340","article-title":"Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer\u2019s disease: implications for amyloid imaging","volume":"28","author":"Beach","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2019.01.004_bib0135","first-page":"S3","article-title":"The amyloid hypothesis on trial","volume":"559","author":"Martin","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coph.2019.01.004_bib0140","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0145","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.21031","article-title":"Impact of Alzheimer\u2019s pathology on cognitive trajectories in nondemented elderly","volume":"60","author":"Driscoll","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-170490","article-title":"Cognitive decline in preclinical Alzheimer\u2019s disease: amyloid-beta versus tauopathy","volume":"61","author":"Huber","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2019.01.004_sbref0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0160","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jalz.2007.04.379","article-title":"A chapter in the development of Alzheimer\u2019s disease research: a case study of public policies on the development and funding of research programs","volume":"3","author":"Khachaturian","year":"2007","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0170","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awv316","article-title":"Alzheimer\u2019s disease in the 100 years since Alzheimer\u2019s death","volume":"138","author":"Ryan","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.coph.2019.01.004_bib0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","article-title":"The prevalence and malignancy of Alzheimer\u2019s Disease. A major killer","volume":"33","author":"Katzman","year":"1976","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0180","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/j.1582-4934.2010.01159.x","article-title":"Should the word \u2018dementia\u2019 be forgotten?","volume":"14","author":"Jellinger","year":"2010","journal-title":"J Mol Cell Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0185","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.01.004_bib0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.coph.2019.01.004_sbref0195","series-title":"Early Alzheimer\u2019s Disease: Developing Drugs for Treatment. Guidance for Industry. Draft Guidance","author":"FDA","year":"2018"},{"key":"10.1016\/j.coph.2019.01.004_bib0200","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0210","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jalz.2015.12.006","article-title":"Diabetes is associated with cerebrovascular but not Alzheimer\u2019s disease neuropathology","volume":"12","author":"Abner","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0215","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10654-018-0418-4","article-title":"Will biomarker-based diagnosis of Alzheimer\u2019s disease maximize scientific progress? Evaluating proposed diagnostic criteria","volume":"33","author":"Glymour","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.coph.2019.01.004_bib0220","first-page":"346","article-title":"Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease","volume":"10","author":"Ill\u00e1n-Gala","year":"2018","journal-title":"Alzheimers Dement: Diagn Asses Dis Monit"},{"key":"10.1016\/j.coph.2019.01.004_bib0225","article-title":"When is Alzheimer\u2019s not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer\u2019s Association Research Framework for Alzheimer\u2019s Disease","author":"McCleery","year":"2018","journal-title":"Age Ageing"},{"key":"10.1016\/j.coph.2019.01.004_sbref0230","series-title":"Is the Rising Storm of Alzheimer\u2019s Disease Stoppable?","author":"Khachaturian","year":"2018"},{"key":"10.1016\/j.coph.2019.01.004_bib0235","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jalz.2018.05.006","article-title":"The National Institute on Aging-Alzheimer\u2019s Association Framework on Alzheimer\u2019s disease: application to clinical trials","volume":"15","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0240","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.coph.2019.01.004_sbref0245","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer\u2019s disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coph.2019.01.004_bib0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/2051-5960-1-62","article-title":"The airbag problem\u2013a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer\u2019s disease","volume":"1","author":"Krstic","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.coph.2019.01.004_bib0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.phrs.2018.02.014","article-title":"Precision pharmacology for Alzheimer\u2019s disease","volume":"130","author":"Hampel","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coph.2019.01.004_bib0260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jalz.2018.06.3058","article-title":"A systems-based model of Alzheimer\u2019s disease","volume":"15","author":"Tang","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0265","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3233\/JAD-160152","article-title":"Microbes and Alzheimer\u2019s disease","volume":"51","author":"Itzhaki","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2019.01.004_bib0270","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fnagi.2018.00224","article-title":"Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer\u2019s disease?","volume":"10","author":"Fulop","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1059","article-title":"Amyloid-\u03b2 peptide protects against microbial infection in mouse and worm models of Alzheimer\u2019s disease","volume":"8","author":"Kumar","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2018.06.030","article-title":"Alzheimer\u2019s disease-associated \u03b2-amyloid is rapidly seeded by Herpesviridae to protect against brain infection","volume":"99","author":"Eimer","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2019.01.004_bib0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuron.2018.05.023","article-title":"Multiscale analysis of independent Alzheimer\u2019s Cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus","volume":"99","author":"Readhead","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2019.01.004_bib0290","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","article-title":"The antimicrobial protection hypothesis of Alzheimer\u2019s disease","volume":"14","author":"Moir","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0295","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tins.2018.07.001","article-title":"Microbes and Alzheimer\u2019s disease: new findings call for a paradigm change","volume":"41","author":"Haas","year":"2018","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0300","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fnagi.2018.00324","article-title":"Corroboration of a major role for herpes simplex virus type 1 in Alzheimer\u2019s disease","volume":"10","author":"Itzhaki","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fnagi.2015.00046","article-title":"Historic evidence to support a causal relationship between spirochetal infections and Alzheimer\u2019s disease","volume":"7","author":"Miklossy","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0310","series-title":"The End of Alzheimer\u2019s. The Brain and Beyond","first-page":"275","author":"Lewis","year":"2017"},{"key":"10.1016\/j.coph.2019.01.004_bib0315","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0320","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2019.01.004_bib0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0330","first-page":"571","article-title":"Toward common mechanisms for risk factors in Alzheimer\u2019s syndrome","volume":"3","author":"Medina","year":"2017","journal-title":"Alzheimers Dement Transl Res Clin Inter"},{"key":"10.1016\/j.coph.2019.01.004_bib0335","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Internal Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0340","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S1474-4422(15)00153-2","article-title":"Prevention of sporadic Alzheimer\u2019s disease: lessons learned from clinical trials and future directions","volume":"14","author":"Andrieu","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2019.01.004_bib0345","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/475S15a","article-title":"Prevention is better than cure","volume":"475","author":"Gandy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2019.01.004_bib0350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/M17-3026","article-title":"Prevention of late-life dementia: no magic bullet","volume":"68","author":"Larson","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0355","unstructured":"Von Radovitz J: Dementia will soon be controlled just like HIV, says research institute. Independent, December 14, 2016. Available from: https:\/\/www.independent.co.uk\/life-style\/health-and-families\/health-news\/dementia-alzheimers-controlled-hiv-research-institute-health-a7473256.html."},{"key":"10.1016\/j.coph.2019.01.004_bib0360","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1172\/JCI97509","article-title":"Blood will out: vascular contributions to Alzheimer\u2019s disease","volume":"128","author":"Strickland","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2019.01.004_bib0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/d41586-018-07352-7","article-title":"Be open about drug failures to speed up drug research","volume":"363","author":"Alteri","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coph.2019.01.004_bib0370","series-title":"Stat News","article-title":"As Alzheimer\u2019s drug developers give up on today\u2019s patients, where is the outrage?","author":"Begley","year":"2018"},{"key":"10.1016\/j.coph.2019.01.004_bib0375","first-page":"22","article-title":"Outcomes assessment in clinical trials of Alzheimer\u2019s disease and its precursors: readying for short-term and long-term clinical trial needs","volume":"14","author":"Posner","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.coph.2019.01.004_bib0380","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.361.6405.838","article-title":"The Alzheimer\u2019s gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease","volume":"361","author":"Kaiser","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.coph.2019.01.004_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-0009.2005.00432.x","article-title":"AIDS and the American health polity: the history and prospects of a crisis of authority","volume":"83","author":"Fox","year":"2005","journal-title":"Milbank Q"},{"key":"10.1016\/j.coph.2019.01.004_bib0390","first-page":"145","article-title":"Europe\u2019s shifting response to HIV\/AIDS: from human rights to risk management","volume":"18","author":"Smith","year":"2016","journal-title":"Health Hum Rights"},{"key":"10.1016\/j.coph.2019.01.004_bib0395","unstructured":"Anderson-Minshall J: These HIV pharmaceutical companies made fortune\u2019s \u2018change the world\u2019 list. hivplusmag. September 1, 2016. Available from: made-fortunes-change-world-list."},{"key":"10.1016\/j.coph.2019.01.004_bib0400","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1758-2652-14-15","article-title":"Driving a decade of change: HIV\/AIDS, patents and access to medicines for all","volume":"14","author":"Hoen","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.coph.2019.01.004_bib0405","series-title":"Impact of Pharmaceutical Innovation in HIV\/AIDS Treatment during the Highly Active Antiretroviral Therapy (HAART) Era in the US, 1987\u20132010: An Epidemiologic and Cost-impact Modeling Case Study","author":"Lacey","year":"2014"},{"key":"10.1016\/j.coph.2019.01.004_bib0410","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coph.2019.01.004_sbref0415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","article-title":"A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease","volume":"76","author":"Karran","year":"2014","journal-title":"Annal Neurol"},{"key":"10.1016\/j.coph.2019.01.004_sbref0420","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.trci.2017.04.005","article-title":"Phase II clinical trials of anti\u2013\u03b2-amyloid antibodies: when is enough, enough?","volume":"3","author":"Gold","year":"2017","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"10.1016\/j.coph.2019.01.004_bib0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-015-0153-y","article-title":"The need for thorough phase II studies in medicines development for Alzheimer\u2019s disease","volume":"7","author":"Gray","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.coph.2019.01.004_bib0430","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12491","article-title":"Lessons learned from alzheimer disease: clinical trials with negative outcomes","volume":"11","author":"Cummings","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.coph.2019.01.004_bib0435","unstructured":"Garde D: Biogen\u2019s \u2018positive\u2019 Alzheimer\u2019s trial has a problem with small numbers. STATNews October 25, 2018. Available from: https:\/\/www.statnews.com\/2018\/10\/25\/biogen-positive-alzheimers-trial-has-a-problem-with-small-numbers\/."},{"key":"10.1016\/j.coph.2019.01.004_bib0440","unstructured":"Carroll J.: Eisai: Biogen battered by controversy over PhII Alzheimer\u2019s study after posting positive results. Endpoints News, July 26, 2018. Available from: https:\/\/endpts.com\/eisai-biogen-outline-an-impressive-30-and-47-advantage-for-theiralzheimers-drug-ban."},{"key":"10.1016\/j.coph.2019.01.004_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0450","unstructured":"Carroll J: Biogen, Eisai fight back against accusations their big BAN2401 study was skewed\u2014but this fight isn\u2019t over yet. Stat News, October 25, 2018, Available from: https:\/\/endpts.com\/biogen-eisai-fight-back-against-accusations-their-big-ban2401-study-was-skewed-but-this-fight-isnt-over-yet\/."},{"key":"10.1016\/j.coph.2019.01.004_bib0455","unstructured":"Begley S: New prize offers $2 million for finding key to Alzheimer\u2019s in past research. STATNews, November 5, 2018. Available from: https:\/\/www.statnews.com\/2018\/11\/05\/prize-alzheimers-past-research\/."},{"key":"10.1016\/j.coph.2019.01.004_bib0460","unstructured":"Norrins LC: It\u2019s time to find the \u201cAlzheimer\u2019s Germ\u201d Available from: https:\/\/alzgerm.org\/wp-content\/uploads\/alzgerm-org-its-time-to-search-germ-full-white-paper-9-4-2018.pdf."},{"key":"10.1016\/j.coph.2019.01.004_sbref0465","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0197-4580(00)00211-6","article-title":"Copernicus revisited: amyloid beta in Alzheimer\u2019s disease","volume":"22","author":"Joseph","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.coph.2019.01.004_sbref0470","series-title":"The End of Alzheimer\u2019s. The Brain and Beyond","first-page":"27","author":"Lewis","year":"2017"},{"key":"10.1016\/j.coph.2019.01.004_bib0475","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0531-5565(97)00057-0","article-title":"The Alzheimerization of aging: a brief update","volume":"33","author":"Adelman","year":"1998","journal-title":"Exp Gerentol"},{"key":"10.1016\/j.coph.2019.01.004_bib0480","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1532-5415.2003.51072.x","article-title":"The Alzheimerization of dementia research","volume":"51","author":"Royall","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.coph.2019.01.004_bib0485","unstructured":"MacFarquhar L: The comforting fictions of dementia care. New Yorker, October 8, 2018. Available from: https:\/\/www.newyorker.com\/magazine\/2018\/10\/08\/the-comforting-fictions-of-dementia-care."},{"key":"10.1016\/j.coph.2019.01.004_bib0490","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2019.01.004_bib0495","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.01.004_bib0500","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0505","unstructured":"Silverman E: Bapi is a bust: Pfizer & J&J Alzheimer Med fails. PharmaBlog, August 7th, 2012. Available from: http:\/\/www.pharmalot.com\/2012\/08\/bapi-is-a-bustpfizer-jj-alzheimer-med-fails\/."},{"key":"10.1016\/j.coph.2019.01.004_bib0510","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Henley","year":"2009","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.coph.2019.01.004_bib0515","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","article-title":"Lessons from a failed \u03b3-secretase Alzheimer trial","volume":"159","author":"De Strooper","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coph.2019.01.004_bib0520","unstructured":"FDA: 22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results, January, 2017. Available from: https:\/\/www.fda.gov\/downloads\/AboutFDA\/ReportsManualsForms\/Reports\/UCM535780.pdf."},{"key":"10.1016\/j.coph.2019.01.004_bib0525","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.coph.2019.01.004_bib0530","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.coph.2019.01.004_bib0535","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1742-2094-10-70","article-title":"Intravenous immunoglobulin and Alzheimer\u2019s disease: what now?","volume":"10","author":"Loeffler","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.coph.2019.01.004_bib0540","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enantiomers of flurbiprofen target \u03b3-secretase and lower A\u03b242 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2019.01.004_bib0545","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer\u2019s disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2019.01.004_bib0550","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.coph.2019.01.004_bib0555","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0560","unstructured":"Carroll J: The Alzheimer\u2019s R&D odyssey comes to another fork in the road, Endpoints News, April 2, 2018. Available from: https:\/\/endpts.com\/special\/the-alzheimers-rd-odyssey-comes-to-another-fork-in-the-road\/."},{"key":"10.1016\/j.coph.2019.01.004_bib0565","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2019.01.004_bib0570","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2019.01.004_bib0575","unstructured":"Taylor NP: Roche halts phase 3 anti-Abeta Alzheimer\u2019s test as AD flops rack up, Fierce Biotech, January 30, 2019. Available from: https:\/\/www.fiercebiotech.com\/biotech\/roche-halts-phase-3-anti-abeta-alzheimer-s-trials-for-futility."},{"key":"10.1016\/j.coph.2019.01.004_bib0580","unstructured":"Lowe D: A critical appraisal ofamyloid-\u03b2 targeting therapies for Alzheimer disease. In the Pipeline, January 30, 2019. Available from: https:\/\/blogs.sciencemag.org\/pipeline\/archives\/2019\/01\/30\/another-alzheimers-antibody-fails-there-will-be-more."},{"key":"10.1016\/j.coph.2019.01.004_bib0585","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid- \u03b2- targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.coph.2019.01.004_bib0590","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3233\/JAD-142208","article-title":"Systematic review of the relationship between amyloid-\u03b2 levels and measures of transgenic mouse cognitive deficit in Alzheimer\u2019s disease","volume":"44","author":"Foley","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.coph.2019.01.004_bib0595","doi-asserted-by":"crossref","first-page":"eaau3333","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer\u2019s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Sci. Adv."}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:49:55Z","timestamp":1761461395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":119,"alternative-id":["S1471489218301796"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.004","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}